ClinicalTrials.gg
RecruitingNCT05761028Updated Dec 15, 2023

A Study of CM310 in Subjects With Moderate to Severe Asthma

A Phase 2/3 interventional study of CM310 and Placebo in Moderate to Severe Asthma, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
31st of 182
600 · median 203
Started
2023
with 22 others
Phase 2/3
3 of 251
1 open now
Primary completion
2032-05
later than 94 of 95 live
Registered
135th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 31st largest by planned enrollment of the 182 interventional ones that give a count, is one of 23 that started in 2023, is one of 3 in phase 2/3, reaches primary completion later than 94 of the 95 other live ones, and was the 135th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma.

The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.

03

Conditions studied

  • Moderate to Severe Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to understand the study and voluntarily sign the form.
  2. Age ≥12 and ≤75 years old, male or female, weight ≥40 kg.
  3. The subject has been diagnosed with asthma for at least 1 year, and the current disease status meets the diagnostic criteria of GINA 2022.
  4. Pre-bronchodilator measured ≤ 80% of the normal predicted value at screening and baseline visits (V1 and V2).
  5. A positive bronchodilation test (≥12% increase in the FEV1 post-bronchodilator and an absolute FEV1 increase of ≥200 mL) within 24 months before consent or at screening.
  6. The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent.
  7. Asthma Control Questionnaire-5 (ACQ-5) score ≥1.5 at screening and baseline visits (V1 and V2).
  8. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before consent, and have not experienced a severe asthma exacerbation event within 1 month before consent, with at least one severe asthma exacerbation event occurring during treatment with medium-to-high dose ICS.
  9. Subjects (including partners) have no plans to have children and voluntarily use highly effective within 3 months after the last dose of study drug from the date of signing the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Received biological agents with the same therapeutic purpose within 6 months before signing the .
  2. Prior disease or inflammatory treatment with biologic agents/systemic agents within 8 weeks or 5 half- lives (whichever is longer) prior to informed consent.
  3. Received immune globulin or blood products within 30 days before informed consent.
  4. Subjects treated with systemic (except for topical, ophthalmic, or intranasal corticosteroids) from 4 weeks before signing the informed consent to the date of randomization.
  5. Received live or attenuated vaccine within 3 months before informed consent signing or planned to receive live or attenuated vaccine during the study period.
  6. Initiation of desensitization therapy within 3 months before informed consent.
  7. Underwent bronchial thermoplasty within 12 months before informed consent.
  8. Current smokers or former smokers who quit smoking less than 6 months or former smokers who quit smoking more than 6 months with a smoking history of more than 10 pack-years.
  9. (COPD) or other lung disease that may impair lung function, as judged by the investigator.
  10. Active infection or acute infection requiring systemic anti-infective therapy from 4 weeks before enrollment to the time of randomization.
  11. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection, even if the infection has resolved; Or the presence of unusual frequent, recurrent, or prolonged infections.
  12. History of : subjects with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix are eligible to enter the study if they have completed curative treatment for at least 12 months before signing the informed consent. Subjects with other malignancies are allowed to enter the study if they have completed curative treatment for at least 5 years before signing the informed consent.
  13. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator may affect the evaluation of the drug, including but not limited to: severe neurological disease, history of severe mental disorder, major cardiovascular disease, diabetes mellitus poorly controlled by intensive treatment, interval prolongation, or persistent arrhythmia.
  14. Major surgery within 8 weeks prior to informed consent or planned surgery requiring general anesthesia or hospitalization for > 1 day during the study period.
  15. Fertile women with positive pregnancy test results during screening; Pregnant or lactating women.
  16. Positive screening serologic test for or treponema pallidum.
  17. Chronic virus or virus infection.
  18. Subjects with abnormal liver and kidney function, such as or alanine aminotransferase>3 × , or serum creatinine>1.5 × ULN.
  19. Have systemic diseases other than asthma that result in an elevated peripheral blood eosinophil count or other diseases such as helminth parasitic infections for which standard treatment is not received or does not respond.
  20. Allergy or intolerance to components of CM310 injection or placebo or history of severe drug allergy or anaphylactic shock.
  21. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent.
  22. Subjects who have used heavy alcohol within 3 months before screening.
  23. History of drug abuse within 5 years before signing informed consent.
  24. The investigator considers that there are any conditions that may prevent the subject from completing the study or present a significant risk to the subject or other factors that may reduce the likelihood of enrollment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    CM310 high dose

    CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then high dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.

    Drug: CM310

  • Experimental
    CM310 low dose

    CM310 is injected subcutaneously (SC) with a loading dose at the first dose, and then low dose thereafter, once every 2 weeks (Q2W) for a total of 26 doses.

    Drug: CM310

  • Placebo comparator
    Placebo

    Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 26 doses.

    Other: Placebo

Interventions

  • DrugCM310

    CM310 Recombinant Humanized Monoclonal Antibody Injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Annualized rate of severe asthma exacerbations

    Time frame: 52 weeks

Secondary outcomes

  1. Change from baseline in pre-bronchodilator Forced expiratory volume in 1 second (FEV1) at Week 12

    Time frame: 56 weeks

  2. Rate of change from baseline in pre-bronchodilator FEV1 at Week 12

    Time frame: 56 weeks

  3. Change from baseline in FEV1 percentage of predicted value (FEV1% Pred)

    Time frame: 56 weeks

  4. Change from baseline in Peak diurnal and nocturnal expiratory flow (PEF)

    Time frame: 56 weeks

  5. Change from baseline in Forced vital capacity (FVC)

    Time frame: 56 weeks

  6. Change from baseline in Forced Expiratory Flow (FEF) 25-75%

    Time frame: 56 weeks

  7. Change from baseline in FEV1 after the use of bronchodilator

    Time frame: 56 weeks

  8. Annualized rate of subjects experiencing the event of loss of asthma control (LOAC)

    Time frame: 52 weeks

  9. Annualized rate of severe asthma exacerbations leading to hospitalization or emergency department observation

    Time frame: 52 weeks

  10. Time to the first onset of the severe asthma exacerbation event

    Time frame: 52 weeks

  11. Time to the onset of the first event of LOAC

    Time frame: 52 weeks

  12. Change from baseline in the Asthma Control Questionnaire-5 (ACQ-5) score at each evaluation time point

    Time frame: 56 weeks

  13. Change from baseline in asthma symptom score at each evaluation time point

    Time frame: 56 weeks

  14. Change from baseline in the Standardized Asthma Quality of Life Questionnaire (AQLQ(S)) score at each evaluation time point

    Time frame: 56 weeks

  15. Change from baseline in the number of inhalations of SABA

    Time frame: 56 weeks

  16. Incidence of Adverse events (AEs)

    Time frame: 56 weeks

  17. The plasma concentration of CM310

    Time frame: 56 weeks

  18. Change from baseline in human thymus and activation-regulated chemokine (TARC)

    Time frame: 56 weeks

  19. Change from baseline in total IgE (immunoglobulin E)

    Time frame: 56 weeks

  20. Change from baseline in fractional exhaled nitric oxide (FeNO)

    Time frame: 56 weeks

  21. Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs)

    Time frame: 56 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for May 2032, 109 months after the start.

Of 14 phase 2/3 interventional studies under Asthma, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 109 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2023
First posted
Mar 9, 2023
StartActual
Apr 28, 2023
Primary completionEst.
May 2032
CompletionEst.
May 2032
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05761028
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Apr 28, 2023
Primary completion
May 2032 (estimated)
Completion
May 2032 (estimated)
Last update
Dec 15, 2023

Study contacts

Wang Wenjuan
Contact
wangwenjuan01@cspc.cn
010-63942533 ext. 100036

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion